ASENT 2022
ANNUAL MEETING

Virtual Neuroscience and Neurotherapeutics Conference

ADVANCE PROGRAM

Opening Symposium:
February 28, 2022

Virtual Meeting
Feb 28 - Mar 3, 2022

REGISTER TODAY: https://asent2022reg.eventbrite.com
ASENT 2022 Annual Meeting

The American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting offers scientific symposia featuring leading-edge research in translational neurology and neuroscience, exciting and engaging poster sessions, and pipeline presentations to keep you at the forefront of what to expect in the neurotherapeutics drug and device markets.

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>About ASENT</td>
<td>p. 2</td>
</tr>
<tr>
<td>Schedule at a Glance</td>
<td>p. 3</td>
</tr>
<tr>
<td>Detailed Virtual Program</td>
<td>p. 4</td>
</tr>
<tr>
<td>Registration Rates and Information</td>
<td>p. 8</td>
</tr>
<tr>
<td>Board of Directors and Program Committee</td>
<td>p. 9</td>
</tr>
</tbody>
</table>
About ASENT 2022

Annual Meeting Overview
ASENT 2022 is the premier neurotherapeutics conference where senior executives from leading payers, providers, employers, academic institutions, investors, fast-growing startups, pharma, policymakers, advocate organizations, funders and innovation centers in the neurology and neuroscience space gather to ask one question: how can we improve the process of bringing neurotherapeutics to market?

The plenary sessions, panel discussions, networking meetings, outstanding pipeline presentations and poster sessions will focus on the latest science in neurotherapeutics including innovations in rare disease, antisense technology across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices.

MEETING DETAILS

ASENT 2022 Meeting Dates
Monday, February 28 - Thursday, March 3, 2022

VIRTUAL FORMAT

ABSTRACT SUBMISSIONS
Open through December 13, 2022
https://www.eventbrite.com/e/189784930837

REGISTRATION
Visit: https://asent2022reg.eventbrite.com

Meeting Location
ONLINE

WHO ATTENDS

Physician-Scientists
Neurologists
Neuroscientists
Fellows
Postdocs
Trainees
Founders
Funders
Investors
Industry Leader
NonProfit Organizations
(NORD, Alzheimer’s Assoc. etc.)
Journal Editors
Drug and Device Companies
Communication Companies
Representatives from NIH, NIA, NIDA, NINDS and FDA

WHAT IS ASENT?
The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of novel and improved therapies for diseases and disorders of the nervous system.
### MONDAY, FEBRUARY 28, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m. – 12:00 p.m.</td>
<td><strong>Presidential Symposium</strong>&lt;br&gt;Rare Neurological Diseases – presented in partnership with National Organization for Rare Disorders (NORD)</td>
</tr>
<tr>
<td>12:00 p.m. – 12:15 p.m.</td>
<td>Break</td>
</tr>
<tr>
<td>12:15 p.m – 1:30 p.m.</td>
<td><strong>Concurrent Symposia</strong>&lt;br&gt;Antisense Oligonucleotide Therapy in Rare Neurological Diseases&lt;br&gt;Emerging Brain Lipid Pharmacology for Neurodegenerative Disorder</td>
</tr>
<tr>
<td>1:30 p.m. – 2:30 p.m.</td>
<td><strong>Sponsored Symposium</strong></td>
</tr>
<tr>
<td>2:30 p.m. – 3:00 p.m.</td>
<td><strong>Poster Discussion</strong></td>
</tr>
</tbody>
</table>

### TUESDAY, MARCH 1, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m. – 11:15 p.m.</td>
<td><strong>Plenary Session</strong>&lt;br&gt;Alzheimer’s Disease After Aducanumab</td>
</tr>
<tr>
<td>11:15 a.m. – 11:30 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>11:30 a.m – 12:45 p.m.</td>
<td><strong>Concurrent Symposia</strong>&lt;br&gt;Devices and Software as Therapeutics for Substance Use Disorders (SUD)&lt;br&gt;Translational Bioinformatics in Drug Repurposing and combination therapy development for Alzheimer's Disease</td>
</tr>
<tr>
<td>12:45 p.m. – 1:00 p.m.</td>
<td>Break</td>
</tr>
<tr>
<td>1:00 p.m. – 3:00 p.m.</td>
<td><strong>Pipeline Presentations</strong>&lt;br&gt;Emerging Neurotherapeutics Presentations</td>
</tr>
</tbody>
</table>

### WEDNESDAY, MARCH 2, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m. – 11:15 p.m.</td>
<td><strong>Plenary Session</strong>&lt;br&gt;Emerging Science of the Exposome and Its Significance to Neurotherapeutics</td>
</tr>
<tr>
<td>11:15 a.m. – 11:30 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>11:30 a.m – 12:45 p.m.</td>
<td><strong>Concurrent Symposia</strong>&lt;br&gt;Innovative Treatments for Rare Neurodevelopmental Diseases&lt;br&gt;The Use of Digital Monitoring Devices in Neurological Clinical Studies</td>
</tr>
<tr>
<td>12:45 p.m. – 1:00 p.m.</td>
<td>Break</td>
</tr>
<tr>
<td>1:00 p.m. – 3:00 p.m.</td>
<td><strong>Pipeline Presentations</strong>&lt;br&gt;Emerging Neurotherapeutics Presentations</td>
</tr>
</tbody>
</table>

### THURSDAY, MARCH 3, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m. – 11:30 p.m.</td>
<td><strong>Plenary Session</strong>&lt;br&gt;Covid-19 and The Brain: Update 2022</td>
</tr>
<tr>
<td>11:30 a.m. – 11:45 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>11:45 a.m – 1:00 p.m.</td>
<td><strong>Concurrent Symposia</strong>&lt;br&gt;Not a One-Trick Pony: Repurposing Established Drugs for New Neurological Indications&lt;br&gt;New Approaches to Pain Therapeutics R&amp;D: Models and Results from Academic and Industry Sectors</td>
</tr>
<tr>
<td>1:00 p.m. – 1:15 p.m.</td>
<td>Break</td>
</tr>
<tr>
<td>1:15 p.m. – 2:15 p.m.</td>
<td><strong>Sponsored Symposium</strong></td>
</tr>
<tr>
<td>2:15 p.m. – 2:45 p.m.</td>
<td><strong>Poster Discussion</strong></td>
</tr>
</tbody>
</table>
**MONDAY, FEBRUARY 28, 2022**

### Presidential Symposium

**Rare Neurological Diseases – presented in partnership with National Organization for Rare Disorders (NORD)**

This symposium will include the global view of Rare Diseases therapeutic development through the lens of the National Organization for Rare Disorders including barriers and successes. Presentations will feature examples such as ASO's and the Batten disease story, as well as drug development in Duchenne Dystrophy.

**CHAIR:** Bennett Lavenstein, MD, Children's National Hospital  
**CO-CHAIR:** Thomas Sutula, MD, PhD, University of Wisconsin, Madison

**FACULTY**  
Peter Saltonstall, National Organization of Rare Disorders  
Timothy Yu, MD, PhD, Boston Children's Hospital  
Edward Neilan, MD, PhD, National Organization of Rare Disorders  
Edward Kaye, MD, Stoke Therapeutics

### Break

12:00 p.m. – 12:15 p.m.

### Concurrent Symposia

#### Antisense Oligonucleotide Therapy in Rare Neurological Diseases

We have demonstrated that gene modification of a previously untreatable disease, spinomuscular atrophy, is feasible. Here, we will explore how to apply these advances more broadly to rare neurological diseases. Developing meaningful interventions will require coordination across multiple domains and stakeholders. The session will discuss recent advances in antisense oligonucleotide therapy, including delivery, toxicity, manufacturing, clinical trial design and regulatory issues.

**CHAIR:** Bryan J. Traynor, MD, PhD, National Institutes of Health, National Institute on Aging  
**CO-CHAIR:** C. Anthony Altar, PhD, Splice Therapeutics

**FACULTY**  
Peter Hagedorn, MSc, PhD, Roche Pharma  
Matthew Wood, MD, DPhil, University of Oxford  
Jonathan Watts, University of Massachusetts Medical School

#### Emerging Brain Lipid Pharmacology for Neurodegenerative Disorder

Lipids account for up to 50% of the brain’s dry weight and comprise thousands of distinct biochemical structures whose subcellular and intracellular expression regulates many levels of neurobiology including organelle homeostasis, synaptic function, stress responses, cell death, inflammation and repair. Not surprisingly, a key role for lipid biochemistry dysregulation has been emerging in neurological disorders involving myelin repair, neuroinflammation, and neurodegeneration. Indeed, the major genetic risk factors driving Alzheimer’s disease and Parkinson’s disease, the most common neurodegenerative disorders, participate in lipid homeostasis (APOE4 and GBA respectively). Advances in genomic, proteomic and lipidomic technologies as well as translational model systems are providing new opportunities for pharmacological approaches to regulate brain lipids. Several such approaches are currently in clinical development and are taking advantage of readily available peripheral lipid biomarkers.

**CHAIR:** Ajay Verma, MD, Yumanity  
**CO-CHAIR:** Aditya Joshi, MD, University of Pennsylvania

**FACULTY**  
Peter Lansbury, PhD, Bial Biotech  
Jeroen Bogie, PhD, Hasselt University  
Jason Ulrich, PhD, Washington University at St. Louis  
Ajay Verma, MD, Yumanity

### Sponsored Symposia

1:30 p.m. – 2:30 p.m.

### Poster Discussion

2:30 p.m. – 3:30 p.m.
### TUESDAY, MARCH 1, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 a.m. – 11:15 p.m.</td>
<td><strong>Plenary Session</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Alzheimer's Disease After Aducanumab</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The goal of the symposium is to present the economic and healthcare industry implications of the controversial regulatory approval of Aducanumab, a fair-minded review of the evidence, the process, an overview of the implications for future Alzheimer’s and other neurologic drug development as well as other research areas in AD that are possible, such as Amyloid backups, Tau, and inflammation.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHAIR: Andrew J. Cole, MD, FRCP(C), Harvard Medical School</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FACULTY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jalayne Arias, JD, MA, University of California, San Francisco</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Karl Herrup, PhD, University of Pittsburgh School of Medicine</td>
<td></td>
</tr>
<tr>
<td>11:15 a.m. – 11:30 a.m.</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>11:30 a.m. – 12:45 p.m.</td>
<td><strong>Concurrent Symposia</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Devices and Software as Therapeutics for Substance Use Disorders (SUD)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exacerbated by COVID-19, the opioid epidemic continues to ravage the United States. In addition to canonical pharmacologic and psychological approaches to SUD treatment, innovative device-based therapeutic solutions, including software as medical device, have recently emerged. During this symposium, the executives from some of the most disruptive and innovative device startups in today’s healthcare ecosystem will discuss the opportunities and challenges of this new field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHAIR: Stacie Gutowski, PhD, National Institute of Health, National Institute of Drug Abuse</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FACULTY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Athena Robinson, PhD, Woebot Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yuri Maricich, MD, MBA, Pear Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Navid Khodaparast, PhD, Spark Biomedical</td>
<td></td>
</tr>
<tr>
<td>12:45 p.m. – 1:00 p.m.</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>1:00 p.m. – 3:00 p.m.</td>
<td><strong>Pipeline Presentations</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The ASENT Pipeline Sessions are brief podium presentations. These presentations are derived from the abstract submissions and vetted by our abstract review committee to ensure the highest caliber and most novel research.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHAIR: Stewart Factor, DO, Emory University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CO-CHAIR: Carolyn Tallon, PhD, Johns Hopkins University</td>
<td></td>
</tr>
</tbody>
</table>
### Plenary Session

**Emerging Science of the Exposome and Its Significance to Neurotherapeutics**

The exposome is defined as all exposures a person receives during the lifespan including internal (e.g., microbiome) and external (e.g., physical-chemical, social) sources. Major progress is being made in data collection, curation, and analysis. This session will discuss the exposome concept, significance of the exposome within the neurological disease community, and scientific approaches to advance the field of exposome research and how these could be used in experimental neurotherapeutics.

**CHAIR:** David Jett, PhD, National Institutes of Health

**FACULTY**
- Yuxia Cui, PhD, National Institute of Environmental Health Sciences
- Eva L. Feldman, MD, PhD, University of Michigan

### Concurrent Symposia

#### Innovative Treatments for Rare Neurodevelopmental Diseases

Neurodevelopmental disease-modifying drug discovery is increasing enormously, however, high unmet needs remain. This is notably true for more rare monogenetic disorders, such as Angelman, Rett, and Dravet syndromes, and across modalities (e.g. small molecule, gene therapy and antisense oligonucleotides). This symposium will discuss scientific advances, hurdles in drug development and delivery, and a fair-balanced review of advantages and disadvantages from bench to bedside.

**CHAIR:** Joseph Sullivan, MD, University of California San Francisco

**CO-CHAIR:** Elizabeth Berry-Kravis, MD, PhD, Rush University Medical Center

**FACULTY**
- Allyson Berent, DVM, DACVIM, GeneTx Biotherapeutics
- Rob Komorowski, PhD, Ionis Pharmaceuticals
- Kimberly A. Parkerson, MD, Stoke Therapeutics

#### The Use of Digital Monitoring Devices in Neurological Clinical Studies

In many neurodegenerative diseases, we see the measures of quality of life, mobility, quality of sleep etc., as measurements that may reflect the stage of the disease. While QoL questionnaires rely on subjective reporting of patients, digital monitoring devices can bridge this gap by allowing for quantitative, frequent, reliable and clinically meaningful measurements of the state of patients in their daily lives. This rich dataset can help us monitor the treatment response and disease progression.

**CHAIR:** Sharon Tamir, Karyopharm Therapeutics

**CO-CHAIR:** Suhayl Dhib-Jalbut, MD, Rutgers Health

**FACULTY**
- Jamie Lynn Adams, MD, University of Rochester Medical Center
- Amir Lahav, ScD, Redenlab

### Pipeline Presentations

**Emerging Neurotherapeutics Pipeline Presentations**

**CHAIR:** Stewart Factor, DO, Emory University

**CO-CHAIR:** Carolyn Tallon, PhD, Johns Hopkins University
**THURSDAY, MARCH 3, 2022**

**10:00 a.m. – 11:30 p.m.**  
**Plenary Session**  
**Covid-19 and The Brain: Update 2022**  
This plenary session features Dr. Avindra Nath, MD, PhD, of the NIH, who will address the neurological involvement and potential mechanism(s) of Covid-19 toxicity in the CNS. Our other speakers will describe brain imaging, function, and mechanism studies that reveal long-term CNS consequences of Covid-19 infection in adults and children. Speakers will present up-to-date evidence on how the virus creates CNS damage and compromises functions, as evidenced by sensory, cognitive, and behavioral impairments that last beyond the typical symptoms of Covid-19.

CHAIR: C. Anthony Altar, PhD, Splice Therapeutics

FACULTY  
Avindra Nath, MD, PhD, National Institute of Health, National Institute  
Dr. Ming Lim, Evelina London Children’s Hospital  
Clinton Wright, MD, MS, National Institutes of Health

**11:30 p.m. – 11:45 p.m.**  
**Break**

**11:45 a.m. – 1:00 p.m.**  
**Concurrent Symposia**  
**Not a One-Trick Pony: Repurposing Established Drugs for New Neurological Indications**  
Many diseases have multifactorial pathophysiology, creating an opportunity to treat them with therapies originally developed for different indications. Here, we will discuss the development of products that utilize already established drugs from other fields of medicine for novel neurological indications.

CHAIR: Sharon Tamir, Karyopharm Therapeutics  
COCHAIR: Aditya Joshi, MD, University of Pennsylvania

FACULTY  
Machelle Manuel, PhD, Amylyx  
Shiran Zimri, PhD, Neurosense  
Takashi Yamamura, MD, PhD, National Institute of Neuroscience in Tokyo

**New Approaches to Pain Therapeutics R&D: Models and Results from Academic and Industry Sectors**  
Development of novel pain therapeutics continues to present significant challenges, demonstrated by data showing only a 2% probability of drug approval for Phase I candidate pain therapeutics, compared to an overall 10% probability in other disease areas. Challenges include unknown neurobiological mechanisms of pain, translation of preclinical data, large placebo effects and disease population heterogeneity. Recently, much more emphasis has been placed on the urgent need to develop successful non-addictive therapeutics for pain as a result of efforts to address the opioid crisis. This symposium will include an overview of new models for pain therapeutics that address the challenge of pain therapeutics development from several perspectives including those representing the scientific, process management and financial challenges.

CHAIR: Mary Ann Pelleymounter, PhD, National Institutes of Health/National Institute of Neurological Disorders and Stroke  
COCHAIR: Debra Ehrlich, MD, MS, National Institutes of Health/National Institute of Neurological Disorders and Stroke

FACULTY  
Michael Oshinsky, PhD, National Institutes of Health/National Institutes of Neurologic Disorders and Stroke  
Kelly Knopp Palmer, Eli Lilly and Company  
Haim Belinson, MSc, PhD, BSense BioTherapeutics

**1:00 p.m. – 1:15 p.m.**  
**Break**

**1:15 p.m. – 3:15 p.m.**  
**Sponsored Symposium**

**3:15 p.m. – 3:45 p.m.**  
**Poster Discussion**
ASENT 2022 Registration Options

Registration is now open for the ASENT 2022 Virtual Annual Meeting! Be sure to take a moment to register and join your colleagues for this exciting event!

### REGISTRATION RATES

<table>
<thead>
<tr>
<th>Reg Type</th>
<th>Reg Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharma, Biotech, Medtech</td>
<td>FREE</td>
</tr>
<tr>
<td>Academic Neurology/Neuroscience</td>
<td>FREE</td>
</tr>
<tr>
<td>Government Employee</td>
<td>FREE</td>
</tr>
<tr>
<td>Retired</td>
<td>FREE</td>
</tr>
<tr>
<td>Student/Trainee</td>
<td>FREE</td>
</tr>
<tr>
<td>NGO/Advocacy Organization/Family Foundation</td>
<td>FREE</td>
</tr>
<tr>
<td>Neurotherapeutics Course Alumni</td>
<td>FREE</td>
</tr>
</tbody>
</table>

**NOTE:** We hope to be back in person in 2023. The in person meeting registration rates will be reflective of hotel, travel, food and beverage costs. Please bear this in mind as you budget for the coming year.

**How to Register**

**Step 1:** Visit: [https://asent2022reg.eventbrite.com](https://asent2022reg.eventbrite.com)

**Step 2:** Look for confirmation email

**Step 3:** Follow directions in confirmation email to visit annual meeting platform and complete your profile in advance of the meeting.

**Step 4:** Join the meeting on Feb 28 - Mar 3, 2022

*(don’t worry we’ll remind you)*

**Bonus:** Become a member so you have access to the recorded sessions all year

### ASENT 2022 Session Recordings

All Virtual Annual Meeting registrations also include access to the ASENT 2022 Annual Meeting Sessions Recordings for a period of 7 days. Active ASENT members will have unlimited access to the recordings beyond the initial 7 day period.

ASENT Members will have the ability to watch key sessions on-demand throughout the year. They will be able to take advantage of key sessions they may have missed. Note: Specific sessions and some presentations within a session may not be available if the presenter has not granted permission to repurpose their presentation.

To learn more about ASENT membership, scroll down or contact the ASENT team at caroline@asent.org.
BOARD OF DIRECTORS

EXECUTIVE COMMITTEE
Thomas Sutula, MD, PhD, PRESIDENT
University of Wisconsin
Andrew J. Cole, MD, FRCP(C), VICE PRESIDENT
Massachusetts General Hospital/Harvard Medical School
Martha Morrell, MD, PAST PRESIDENT
NeuroPace

BOARD MEMBERS
Enrique Carrazana, MD
Neurelis, Inc.
Amy Chappell, MD
Eliam
Suhayl Dhib-Jalbut, MD
Rutgers-Robert Wood Johnson Medical School
Tracy Dixon-Salazar, PhD
Lennox Gastaut Foundation
Debra Ehrlich, MD, MS
NINDS
Stewart Factor, DO
Emory University
Gail Farfel, PhD
Zogenix
Toby Ferguson, MD, PhD
Biogen Idec, Inc
Dietrich Haubenberger, MHSc, MD
Neurocrine
Aditya Joshi, MD
University of Pennsylvania
Laura Rosen, MD, PhD
Takeda
Cynthia Rothblum-Oviatt, PhD
RO Scientific
Nancy Santilli, MSN
Human Care Systems
Steve Schachtter, MD
CIMIT/Harvard Medical School
Carolyn Tallon, PhD
Johns Hopkins University
Danilo Vitorovic, MD
University of Vermont
Amir Tamiz, PhD

PROGRAM COMMITTEE

CHAIRS
C Anthony Altar, PhD, Chair
Splice Therapeutics
Sharon Tamir, Co-Chair
Karyopharm Therapeutics

COMMITTEE MEMBERS
Enrique Carrazana, MD
Neurelis, Inc.
Amy Chappell, MD
Eliam
Suhayl Dhib-Jalbut, MD
Rutgers-Robert Wood Johnson Medical School
Tracy Dixon-Salazar, PhD
Lennox Gastaut Foundation
Debra Ehrlich, MD, MS
NINDS
Stewart Factor, DO
Emory University
Gail Farfel, PhD
Zogenix
Wendy Galpern, MD, PhD
Johnson and Johnson
Dietrich Haubenberger, MHSc, MD
Neurocrine
Aditya Joshi, MD
University of Pennsylvania
Laura Rosen, MD, PhD
Takeda
Cynthia Rothblum-Oviatt, PhD
RO Scientific
Nancy Santilli, MSN
Human Care Systems
Steve Schachtter, MD
CIMIT/Harvard Medical School
Carolyn Tallon, PhD
Johns Hopkins University
Danilo Vitorovic, MD
University of Vermont
Amir Tamiz, PhD

Become an ASENT Member
Join a community of professionals in industry, government, academia and advocacy working together to bring neurotherapeutics to market.

Visit: https://members.asent.org/Membership
Register Today:
https://asent2022reg.eventbrite.com